{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:22:57Z","timestamp":1758633777203,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Combined use of photodynamic therapy (PDT) with intravitreal anti-vascular endothelial growth factors (anti-VEGF) agents, such as ranibizumab (IVR) or aflibercept (IVA), has been shown to be effective for treating polypoidal choroidal vasculopathy (PCV). However, it is currently not well established which anti-VEGF agent provides superior outcomes for performing combination therapy. The present study compares the visual outcomes and re-treatment burden of combination therapy of PDT with either IVR or IVA in a European cohort of patients with PCV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis was done on PCV patients who had received combination therapy of PDT with either IVR or IVA. The demographic characteristics, visual outcome, and anti-VEGF re-treatment exposures were analysed and compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of forty-four eyes (<jats:italic>n<\/jats:italic>\u2009=\u200911 male, 25%) were included in the analysis: 7 patients received IVR, 19 started with IVR but switched to IVA (IVS), and 18 received IVA, in combination with PDT. The BCVA improved in all three groups at 6-, 12-, 18-, 24-, 30-, and 36-month follow-ups after PDT, although the improvement was not statistically significant in the IVR group. The number of intravitreal anti-VEGF injections required\/year after PDT was significantly fewer than before PDT. Significantly less eyes in the IVS group attained a good visual acuity of more than 70 ETDRS letters at the final visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both IVR and IVA combined with PDT were effective treatments for the European cohort of patients with PCV. In eyes refractory to IVR, performing PDT promptly may be more beneficial than switching to IVA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05724-4","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T10:03:22Z","timestamp":1654769002000},"page":"3533-3542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort"],"prefix":"10.1007","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2684-4212","authenticated-orcid":false,"given":"Siyin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramandeep","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"5724_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN et al (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.10.001","journal-title":"Prog Retin Eye Res"},{"key":"5724_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s004170000180","volume":"238","author":"BA Lafaut","year":"2000","unstructured":"Lafaut BA, Leys AM, Snyers B et al (2000) Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 238:752\u2013759. https:\/\/doi.org\/10.1007\/s004170000180","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5724_CR3","doi-asserted-by":"publisher","first-page":"e0149978","DOI":"10.1371\/journal.pone.0149978","volume":"11","author":"Y Sakurada","year":"2016","unstructured":"Sakurada Y, Yoneyama S, Sugiyama A et al (2016) Prevalence and genetic characteristics of geographic atrophy among elderly Japanese with age-related macular degeneration. PLoS ONE 11:e0149978. https:\/\/doi.org\/10.1371\/journal.pone.0149978","journal-title":"PLoS ONE"},{"key":"5724_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M et al (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15-22.e2. https:\/\/doi.org\/10.1016\/j.ajo.2007.03.047","journal-title":"Am J Ophthalmol"},{"key":"5724_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3928\/15428877-20091030-07","volume":"40","author":"Y-C Chang","year":"2009","unstructured":"Chang Y-C, Wu W-C (2009) Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg Lasers Imaging Retina 40:576\u2013581. https:\/\/doi.org\/10.3928\/15428877-20091030-07","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"5724_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.eye.6700706","volume":"18","author":"ID Ladas","year":"2004","unstructured":"Ladas ID, Rouvas AA, Moschos MM et al (2004) Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye 18:455\u2013459. https:\/\/doi.org\/10.1038\/sj.eye.6700706","journal-title":"Eye"},{"key":"5724_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00006982-200104000-00004","volume":"21","author":"B Scassellati-Sforzolini","year":"2001","unstructured":"Scassellati-Sforzolini B, Mariotti C, Bryan R et al (2001) Polypoidal choroidal vasculopathy in Italy. Retina 21:121\u2013125. https:\/\/doi.org\/10.1097\/00006982-200104000-00004","journal-title":"Retina"},{"key":"5724_CR8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","volume":"101","author":"S Yadav","year":"2017","unstructured":"Yadav S, Parry DG, Beare NAV, Pearce IA (2017) Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol 101:1377\u20131380. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-310074","journal-title":"Br J Ophthalmol"},{"key":"5724_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen L-J et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453\u20131464. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8","journal-title":"Retina"},{"key":"5724_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AHC (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182\u2013199. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.09.003","journal-title":"Prog Retin Eye Res"},{"key":"5724_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"5724_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","volume":"121","author":"A Oishi","year":"2014","unstructured":"Oishi A, Miyamoto N, Mandai M et al (2014) LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology 121:1151\u20131152. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.037","journal-title":"Ophthalmology"},{"key":"5724_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M et al (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644-651.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.024","journal-title":"Am J Ophthalmol"},{"key":"5724_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K et al (2020) Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol 138:935. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443","journal-title":"JAMA Ophthalmol"},{"key":"5724_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00417-016-3500-1","volume":"255","author":"W Matsumiya","year":"2017","unstructured":"Matsumiya W, Honda S, Otsuka K et al (2017) One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:541\u2013548. https:\/\/doi.org\/10.1007\/s00417-016-3500-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5724_CR16","doi-asserted-by":"publisher","first-page":"16461","DOI":"10.1038\/s41598-017-16476-1","volume":"7","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Sugiyama A et al (2017) Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy. Sci Rep 7:16461. https:\/\/doi.org\/10.1038\/s41598-017-16476-1","journal-title":"Sci Rep"},{"key":"5724_CR17","doi-asserted-by":"publisher","first-page":"e0176100","DOI":"10.1371\/journal.pone.0176100","volume":"12","author":"K Takayama","year":"2017","unstructured":"Takayama K, Kaneko H, Kataoka K et al (2017) Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: retrospective observation study. PLoS ONE 12:e0176100. https:\/\/doi.org\/10.1371\/journal.pone.0176100","journal-title":"PLoS ONE"},{"key":"5724_CR18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00417-013-2323-6","volume":"251","author":"M Saito","year":"2013","unstructured":"Saito M, Iida T, Kano M, Itagaki K (2013) Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 251:2099\u20132110. https:\/\/doi.org\/10.1007\/s00417-013-2323-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5724_CR19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1089\/jop.2013.0044","volume":"29","author":"Y Sakurada","year":"2013","unstructured":"Sakurada Y, Iijima H (2013) Two-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 29:832\u2013836. https:\/\/doi.org\/10.1089\/jop.2013.0044","journal-title":"J Ocul Pharmacol Ther"},{"key":"5724_CR20","doi-asserted-by":"publisher","unstructured":"Liu S, Chhabra R (2021) Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Eye 1\u20136.\u00a0https:\/\/doi.org\/10.1038\/s41433-021-01773-x","DOI":"10.1038\/s41433-021-01773-x"},{"key":"5724_CR21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/app11031194","volume":"11","author":"H-Y Weng","year":"2021","unstructured":"Weng H-Y, Huang T-L, Chang P-Y et al (2021) Comparison of two-year outcome of photodynamic therapy in combination with intravitreal aflibercept or ranibizumab for polypoidal choroidal vasculopathy. Appl Sci 11:1194. https:\/\/doi.org\/10.3390\/app11031194","journal-title":"Appl Sci"},{"key":"5724_CR22","doi-asserted-by":"publisher","first-page":"e0235213","DOI":"10.1371\/journal.pone.0235213","volume":"15","author":"A Ito","year":"2020","unstructured":"Ito A, Maruyama-Inoue M, Kitajima Y et al (2020) Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy. PLoS ONE 15:e0235213. https:\/\/doi.org\/10.1371\/journal.pone.0235213","journal-title":"PLoS ONE"},{"key":"5724_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan CS, Ngo WK, Chen JP et al (2015) EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol 99:624\u2013628. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305674","journal-title":"Br J Ophthalmol"},{"key":"5724_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1136\/bjophthalmol-2014-306432","volume":"99","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A et al (2015) Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol 99:1284\u20131288. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306432","journal-title":"Br J Ophthalmol"},{"key":"5724_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ajo.2015.01.018","volume":"159","author":"A Oishi","year":"2015","unstructured":"Oishi A, Tsujikawa A, Yamashiro K et al (2015) One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 159:853-860.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.018","journal-title":"Am J Ophthalmol"},{"key":"5724_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS et al (2016) Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 165:1\u20136. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.019","journal-title":"Am J Ophthalmol"},{"key":"5724_CR27","doi-asserted-by":"publisher","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond) 27:1013\u20131020; quiz 1021. https:\/\/doi.org\/10.1038\/eye.2013.179","DOI":"10.1038\/eye.2013.179"},{"key":"5724_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","volume":"150","author":"AN Stangos","year":"2010","unstructured":"Stangos AN, Gandhi JS, Nair-Sahni J et al (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150:666\u2013673. https:\/\/doi.org\/10.1016\/j.ajo.2010.05.035","journal-title":"Am J Ophthalmol"},{"key":"5724_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","volume":"148","author":"M Cho","year":"2009","unstructured":"Cho M, Barbazetto IA, Freund KB (2009) Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 148:70-78.e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.02.012","journal-title":"Am J Ophthalmol"},{"key":"5724_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","volume":"98","author":"K Hatz","year":"2014","unstructured":"Hatz K, Pr\u00fcnte C (2014) Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol 98:188\u2013194. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-303444","journal-title":"Br J Ophthalmol"},{"key":"5724_CR31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","volume":"34","author":"M Saito","year":"2014","unstructured":"Saito M, Kano M, Itagaki K et al (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina 34:2192\u20132201. https:\/\/doi.org\/10.1097\/IAE.0000000000000236","journal-title":"Retina"},{"key":"5724_CR32","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","volume":"253","author":"Y Kawashima","year":"2015","unstructured":"Kawashima Y, Oishi A, Tsujikawa A et al (2015) Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253:1471\u20131477. https:\/\/doi.org\/10.1007\/s00417-014-2838-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5724_CR33","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-020-04710-y","volume":"258","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW (2020) Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1677\u20131685. https:\/\/doi.org\/10.1007\/s00417-020-04710-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5724_CR34","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung BJ, Kim JY, Lee JH et al (2019) Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 9:2055. https:\/\/doi.org\/10.1038\/s41598-019-38504-y","journal-title":"Sci Rep"},{"key":"5724_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.survophthal.2018.02.004","volume":"63","author":"I Mantel","year":"2018","unstructured":"Mantel I, Gillies MC, Souied EH (2018) Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol 63:638\u2013645. https:\/\/doi.org\/10.1016\/j.survophthal.2018.02.004","journal-title":"Surv Ophthalmol"},{"key":"5724_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12886-015-0064-5","volume":"15","author":"M Yong","year":"2015","unstructured":"Yong M, Zhou M, Deng G (2015) Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis. BMC Ophthalmol 15:82. https:\/\/doi.org\/10.1186\/s12886-015-0064-5","journal-title":"BMC Ophthalmol"},{"key":"5724_CR37","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R et al (2021) Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11:6759. https:\/\/doi.org\/10.1038\/s41598-021-86014-7","journal-title":"Sci Rep"},{"key":"5724_CR38","unstructured":"New phase III data show Roche\u2019s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients. https:\/\/www.roche.com\/media\/releases\/med-cor-2021-02-12. Accessed 4 May 2022"},{"key":"5724_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee W-K et al (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107\u2013139. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.002","journal-title":"Prog Retin Eye Res"},{"key":"5724_CR40","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1097\/IAE.0000000000001872","volume":"38","author":"TD Lorentzen","year":"2018","unstructured":"Lorentzen TD, Subhi Y, S\u00f8rensen TL (2018) Prevalence of polypoidal choroidal vasculopathy in white patients ith exudative age-related macular degeneration: systematic review and meta-analysis. Retina 38:2363\u20132371. https:\/\/doi.org\/10.1097\/IAE.0000000000001872","journal-title":"Retina"},{"key":"5724_CR41","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/IAE.0000000000000206","volume":"34","author":"SJ Davis","year":"2014","unstructured":"Davis SJ, Lauer AK, Flaxel CJ (2014) Polypoidal choroidal vasculopathy in white patients. Retina 34:2185\u20132191. https:\/\/doi.org\/10.1097\/IAE.0000000000000206","journal-title":"Retina"},{"key":"5724_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K et al (2021) Polypoidal choroidal vasculopathy: consensus nomenclature and non\u2013indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV workgroup. Ophthalmology 128:443\u2013452. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.006","journal-title":"Ophthalmology"},{"key":"5724_CR43","unstructured":"CZARSKA-THORLEY D (2021) Visudyne (verteporfin): Information on the continuing supply restriction until end Q1\/2022. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/visudyne-verteporfin-information-continuing-supply-restriction-until-end-q1-2022. Accessed 2 Jan 2022"},{"key":"5724_CR44","unstructured":"Drugs shortage: continuing shortage of Visudyne (verteporfin). In: The Royal College of Ophthalmologists. https:\/\/www.rcophth.ac.uk\/news-views\/drugs-shortage-continuing-shortage-of-visudyne-verteporfin\/. Accessed 2 Jan 2022"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05724-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T18:06:06Z","timestamp":1666202766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5724"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05724-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript. After the potential risks and benefits were explained in detail, informed consent was obtained from all individual participants included for the treatment and the retrospective chart review in this study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the clinical audit department of the Manchester Royal Eye Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}